A5009700060- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Single-cell and spatial transcriptomics
- Chronic Myeloid Leukemia Treatments
- Viral Infectious Diseases and Gene Expression in Insects
- Virus-based gene therapy research
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Cell Image Analysis Techniques
- Glioma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Childhood Cancer Survivors' Quality of Life
- Neuroblastoma Research and Treatments
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Immune cells in cancer
- Advanced Biosensing Techniques and Applications
- CRISPR and Genetic Engineering
- Hematopoietic Stem Cell Transplantation
- RNA Interference and Gene Delivery
- Lymphoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Nanowire Synthesis and Applications
Stanford University
2016-2025
Stanford Medicine
2019-2024
Stanford Cancer Institute
2022-2024
Texas Scottish Rite Hospital for Children
2018-2023
Palo Alto University
2010-2023
Cancer Prevention Institute of California
2022
Stanford Health Care
2021
Stanford Maternal and Child Health Research Institute
2021
Center for Cancer and Blood Disorders
2019-2021
University of South Carolina
2021
In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children young adults relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).We conducted 2, single-cohort, 25-center, global study pediatric adult patients CD19+ ALL. The primary end point overall rate (the incomplete hematologic recovery) within 3...
Abstract Diffuse intrinsic pontine glioma (DIPG) and other H3K27M-mutated diffuse midline gliomas (DMGs) are universally lethal paediatric tumours of the central nervous system 1 . We have previously shown that disialoganglioside GD2 is highly expressed on cells demonstrated promising preclinical efficacy GD2-directed chimeric antigen receptor (CAR) T 2 , providing rationale for a first-in-human phase I clinical trial (NCT04196413). Because CAR cell-induced brainstem inflammation can result...
Abstract Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten 16 large B cell lymphoma (LBCL) disease after CAR19 treatment had absent or low CD19. Lower surface CD19 density pretreatment was associated To prevent relapse − lo disease, we tested a bispecific CAR targeting and/or CD22 (CD19-22.BB.z-CAR) in phase I clinical trial ( NCT03233854 ) adults relapsed/refractory acute...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. In analysis of global phase II ELIANA trial (ClinicalTrials.gov identifier: NCT02435849), tisagenlecleucel provided...
Adenosine (Ado) mediates immune suppression in the tumor microenvironment and exhausted CD8+ CAR-T cells express CD39 CD73, which mediate proximal steps Ado generation. Here, we sought to enhance cell potency by knocking out CD39, or adenosine receptor 2a (A2aR) but observed only modest effects. In contrast, overexpression of deaminase (ADA-OE), metabolizes inosine (INO), induced stemness enhanced functionality. Similarly, exposure INO augmented function features stemness. profound metabolic...
Purpose The anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel was recently approved to treat relapsed or refractory pediatric acute lymphoblastic leukemia. With a one-time infusion cost of $475,000, is currently the most expensive oncologic therapy. We aimed determine whether effective compared with available treatments. Methods Markov modeling used evaluate in leukemia from US health payer perspective over lifetime horizon. model informed by recent multicenter, single-arm...
BackgroundOutcomes are poor for patients with large B-cell lymphoma who relapse after CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR19). CD22 is a nearly universally expressed surface and the efficacy of CD22-directed CAR (CAR22) in unknown, which was what we aimed to examine this study.MethodsIn single centre, open-label, dose-escalation phase 1 trial, intravenously administered CAR22 at two dose levels (1 million 3 CAR22-positive T cells per kg bodyweight) adult (aged...
Abstract The intensive nutrient requirements needed to sustain T cell activation and proliferation, combined with competition for nutrients within the tumor microenvironment, raise prospect that glucose availability may limit CAR-T function. Here, we seek test hypothesis stable overexpression (OE) of transporter GLUT1 in primary human cells would improve their function antitumor potency. We observe GLUT1OE increases consumption, glycolysis, glycolytic reserve, oxidative phosphorylation,...
Abstract Human CD3+CD4+ Th cells, FOXP3+ T regulatory (Treg) and type 1 (Tr1) cells are essential for ensuring peripheral immune response tolerance, but the diversity of Th, Treg, Tr1 cell subsets has not been fully characterized. Independent functional characterization human Th1, Th2, Th17, follicular helper (Tfh), helped to define unique surface molecules, transcription factors, signaling profiles each subset. However, adequacy these markers recapitulate whole compartment remains...
Abstract Acute lymphoblastic leukemia (ALL) is the most common cancer in children. The highest rates of treatment failure occur specific genetic subsets ALL, including hypodiploid B-cell ALL (B-ALL), for which effective alternative therapies to current intensive chemotherapy treatments have yet be developed. Here, we integrated biochemical and genomic profiling with functional drug assays select agents therapeutic potential against B-ALL. ABT-199, a selective Bcl-2 inhibitor, was reducing...
In many cancers, nivolumab in combination with ipilimumab improves response rates compared either agent alone, but the has not been evaluated childhood cancer. We conducted a phase I/II trial of plus children and young adults recurrent/refractory solid tumors.ADVL1412, Part C assessed safety at two dose levels (DL): DL1 1 mg/kg each drug DL2 3 ipilimumab. D recommended II (RP2D) Ewing sarcoma, rhabdomyosarcoma, osteosarcoma. E tested DL3 (1 ipilimumab) sarcoma rhabdomyosarcoma. Tumor was...